A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Peter Hersey, Jeffrey Sosman, Steven O'Day, Jon Richards, Agop Bedikian, Rene Gonzalez, William Sharfman, Robert Weber, Theodore Logan, Manuela Buzoianu, Luz Hammershaimb, John M. Kirkwood

Research output: Contribution to journalArticle

113 Scopus citations

Fingerprint Dive into the research topics of 'A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α<sub>v</sub>β<sub>3</sub>, ± dacarbazine in patients with stage IV metastatic melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences